Sr. Director, Contract Strategy, Pricing & Operations

About the role

This is a critical leadership position dedicated to driving market access, pricing strategy, and contracting for our best-in-class oncology and hematology therapies. In this high-impact role, you will spearhead US pricing and life-cycle strategies for key products, including Orserdu and Elzonris. Acting as the strategic and financial linchpin between brand, finance, and market access teams, you will lead the team responsible for executing complex deal analytics, optimizing gross-to-net (GTN) performance, and designing comprehensive contracting frameworks to remove access barriers across payors, Specialty Pharmacy Networks, and GPOs. You will also champion operational excellence by ensuring 100% compliance with government pricing regulations—expertly navigating state transparency laws, 340B impacts, and Medicaid models to secure our market leadership in a high-scrutiny sector.

Responsibilities

• Pricing Strategy, Financial Modeling & Gross-to-Net (GTN)
  • Spearhead US pricing for Orserdu and life-cycle strategy for Elzonris, establishing value benchmarks and market leadership for best-in-class oncology and hematology therapies.
  • Formulate, model, and execute price changes for Orserdu and Elzonris, routing PI communications and compendia submissions through internal stakeholders.
  • Manage quarterly and monthly GTN analyses and breakouts for leadership review.
  • Lead the development of deal analytics and scenario models to assess profitability, rebate structures, and Gross-to-Net (GTN) impacts across all commercial channels.
  • Coordinate with brand and finance to deliver segment-specific insight/modeling to inform contract strategy development and impact.
  • Serve as a resource for Licensing and Business Development in assessing price for potential opportunities.
• Payer Contracting, GPO & Distribution Strategy
  • In coordination with Market Access field teams, develop contracting and pricing strategies to ensure profitable uptake of the Stemline portfolio.
  • Establish portfolio-level guardrails and decision frameworks to optimize access across payors, GPOs, specialty distributors, and large provider networks.
  • Lead contracting strategy workshops with payor and GPO teams to remove access barriers for Orserdu.
  • Design Payer Contracting Deal Analytics models for Commercial and Medicare lines of business, sales forecasts by payer plan, and establish standard MSA/Proposal templates.
  • Work closely with Account teams to negotiate and implement contracting strategies and ensure implementation of contract strategies and contracting platforms.
  • In coordination with the commercial trade and distribution team, develop and/or manage Specialty Pharmacy Networks strategy and performance based on aligned brand strategies.
  • Work closely with Market Access field teams and Medical Affairs to develop and evaluate Value-Based Arrangements.
• Government Pricing, Programs & State Transparency
  • Manage a team ensuring 100% compliance with state drug price transparency regulations and government price reporting, effectively mitigating audit risks in the high-scrutiny oncology sector.
  • Lead 340B analysis of distribution changes, contracting initiatives, as well as new federal and state legislation.
  • Oversee Orserdu and Elzonris Medicaid waterfall models.
  • Responsible for Federal Supply Schedule (FSS) contract renewals and contract adherence.
  • Oversee State Price Transparency Reporting including collaborating to maintain state disclosures (e.g., CT, VT, and CO).
  • Oversee the Pharmaceutical Product Stewardship Work Group program enrollment, tracking state forms, and ensuring timely invoice payments.
  • Coordinate with internal and external resources regarding operational activities such as rebates, chargebacks, government reporting, contract writing, and process approvals.
• Government Affairs & Policy Analytics
  • Evaluate the impact of governmental pricing proposals, policies, and regulations (e.g., Most Favored Nation).
  • Support public policy strategy in partnership with Government Affairs by assisting with public comment periods and advocating for small manufacturers.
  • Quantify the financial implications of healthcare reform (e.g., Medicare Part D redesign, inflation rebates, MFN) on the pipeline to inform long-term pricing and contracting tradeoffs.
• Market Intelligence & Field Enablement
  • Develop a deep understanding of the payer environment (both medical and pharmacy benefit), competitive market conditions affecting pricing for our oncology products, and the pharmaceutical industry overall.
  • Translate complex pricing, contracting, and policy landscape shifts into actionable intelligence and tactical materials for field teams.
  • Ensure field readiness for negotiations and optimizing formulary access that can result in pull-through initiatives while safeguarding GTN targets.
  • Monitor the environment and practices for shifts in trends or behaviors, interpret likely impacts, and suggest appropriate actions.
  • Evaluate the changing marketplace and proactively make recommendations on pricing strategies related to managed care, reimbursement environment, federal and state regulations.
• Team Operations & Vendor Administration
  • Lead the onboarding, 30-60-90-day planning, equipment setup, and mid-year reviews for your direct report(s).
  • Create and update regular slide decks and dashboard templates for leadership review.
  • Handle the negotiation, signature, and budget approvals for key consulting partners.
  • Secure and manage data streams across multiple pharmaceutical solution providers.

Requirements

• Bachelor’s degree; preferably in a relevant field (Marketing, Science, Economics, Finance, or related field).
• 10 years of related healthcare business experience.
• Experience in Oncology/Specialty across small and large molecules.
• In-depth understanding of Market Access and Healthcare delivery.
• Analytical skills including problem-solving, forecasting, contract development, and financial modeling.
• Demonstrated negotiation and relationship-building skills.
• Demonstrated ability to manage multiple priorities.
• Strong oral and written communication skills, including a strong focus on customer service.
• High level of expertise in Government Pricing.

Benefits

• Short- and Long-Term Incentive Programs.
• Fidelity 401(k) with 6% company match.
• Anthem Premier PPO and HDHP insurance plans.
• Company-paid Basic Life & AD&D insurance.
• Pre-tax FSA/HSA programs.

Pay

Base Salary Range of $253,000-$305,000.

About us

The Menarini Group is present in 70 countries, and our products are sold in 140 locations worldwide. With the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, Menarini marked its entry into the US oncology market. The company employs around 18,000 people and produces over 500 million packs of drugs annually across 18 manufacturing sites, including a biotech plant for monoclonal antibodies.

Menarini has a strong commitment to oncology, with a pipeline of five investigational compounds for treating various hematological and solid tumors. The acquisition of Stemline Therapeutics strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Key products include:

• Tagraxofusp: A novel, first-in-class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. It is also being evaluated for other CD123+ indications.
• Selinexor: A first-in-class, oral Selective Inhibitor of Nuclear Export compound for hematologic cancers and solid tumors, licensed from Karyopharm Therapeutics for commercialization in Europe, Latin America, and other regions. It is already marketed in the US for multiple myeloma and is under development for solid tumor indications.
• Elacestrant: An oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following FDA approval in January 2023 and a successful launch, it is now available in the US, with EMA approval secured in September 2023.

This is an exciting time to join Menarini Stemline and contribute to shaping its Oncology business.